What Are the Side Effects of Low Dose Naltrexone?

Low dose naltrexone, commonly called LDN, has a side-effect profile that is consistently described across studies as mild and usually short-lived. The most frequently reported issues are vivid dreams, nausea, fatigue, insomnia, and headaches. In clinical trials, the rate of adverse events among people taking LDN often looks remarkably similar to the rate in people taking a placebo, which tells you something useful about how well most people tolerate it. That said, there are a few specific situations where the risks become more serious, and those deserve close attention.

The Side Effects People Actually Report

Across multiple studies and real-world prescribing data, the same handful of complaints show up again and again. Vivid or unusual dreams are probably the single most recognized side effect. In one chronic pain research group, roughly 37 percent of participants taking LDN reported more vivid dreams than usual, making it the standout complaint in that cohort.¹ A retrospective study of one pain physician’s practice found that about half of patients experienced some kind of adverse effect, with nausea being the most common (reported by 18 out of 93 patients), followed by fatigue, vivid dreams, and insomnia.² Of the patients in that study who did report side effects, nearly half said the effects were transient and faded on their own.

In a 12-month randomized trial studying LDN for fibromyalgia, the most common categories of adverse events were nervous system complaints, musculoskeletal pain, gastrointestinal issues, and psychiatric symptoms. The vast majority of events were rated as mild. Nervous system symptoms, including headaches and dizziness, were the one category that showed up more often in the LDN group than in the placebo group, at about 21 percent versus 9 percent.³ Other categories of side effects did not differ meaningfully between the groups.

So if you are starting LDN and notice strange dreams, a slightly upset stomach, or some tiredness in the first days or weeks, you are in common company. These complaints tend to be self-limiting, and many people find they resolve within a few weeks of continuing the medication.

How Side Effects Compare to Placebo

One of the more interesting things about LDN’s side-effect data is how often the placebo group in trials reports nearly identical rates of adverse events. In the 12-month fibromyalgia trial, about 69 percent of participants on LDN reported at least one adverse event over the course of the study, but 72 percent of participants on placebo did too. That is essentially no difference.³ Clinician assessment in that same study found that more than 84 percent of all adverse events were judged not related to the study medication at all. Only about 2 percent were rated as probably or certainly related to LDN.

The chronic pain research group that documented vivid dreams as the leading side effect also found that participants rated LDN as slightly more tolerable than placebo overall, at about 91 percent versus 89.5 percent, a difference that was not statistically significant.¹ The frequency of headaches was a bit higher with LDN than with placebo, though the study noted that more participants would need to be assessed to pin down whether that gap is real.

This pattern is useful context if you are weighing whether to try LDN. When a drug’s side-effect rate in trials barely diverges from the placebo rate, it suggests the drug itself is contributing relatively little to the discomfort people experience. Some of the complaints attributed to LDN may stem from the underlying condition being treated, from the nocebo effect (expecting side effects and then noticing them), or simply from the noise of everyday symptoms being tallied over months.

The Opioid Interaction That Can Be Dangerous

While everyday side effects tend to be mild, there is one interaction with LDN that carries real danger. Standard-dose naltrexone (50 mg) is used to block opioid receptors in people recovering from opioid use disorder, so the connection between naltrexone and opioids is well known. But LDN (typically 1 to 6 mg) works through a different mechanism and does not block receptors in the same sustained way. Instead, LDN’s brief, partial blockade of opioid receptors may cause the body to upregulate its own endogenous opioid system and become hypersensitized to external opioids.

A published case report describes what can go wrong. A patient being treated with LDN for multiple sclerosis received a single standard dose of oxycodone (5 mg) and became profoundly unresponsive, to the point of not reacting to painful stimuli. The patient required emergency naloxone injections and an overnight stay in intensive care.⁴ A 5 mg oxycodone tablet would not normally cause that response in an opioid-naive adult, which makes the case a striking illustration of how LDN can amplify opioid sensitivity.

The authors of that case report noted that standard drug-interaction screening tools in electronic health records flag the combination of naltrexone and opioids as a risk of opioid withdrawal, not opioid hypersensitivity. That means the warning system most hospitals and pharmacies rely on may point clinicians in the wrong direction. If you take LDN, it is worth telling every healthcare provider you see, including emergency room staff and dentists, because an ordinary pain medication prescription could produce an outsized and dangerous reaction.

Serious Adverse Events

Across the studies examined for this article, no serious adverse events were attributed to LDN itself. In the year-long fibromyalgia trial, five serious adverse events occurred (three percent of all participants), four in the LDN group and one in the placebo group. None were considered related to the study medication.³ A safety review covering LDN use in multiple sclerosis, fibromyalgia, and Crohn’s disease concluded that the evidence supports its safety and tolerability across those conditions.⁵

Standard-dose naltrexone (50 mg) carries an FDA black-box warning about liver toxicity, and you will sometimes see that concern raised in discussions about LDN. The doses used in LDN are a fraction of the standard dose, and the clinical data at those low doses have not shown concerning changes in liver enzymes. In the pediatric Crohn’s study described below, researchers specifically monitored serum transaminases (a marker of liver stress) and found no significant abnormalities. That said, most LDN studies are relatively small and short by pharmaceutical standards, so the absence of rare serious events in the existing data does not rule them out with absolute certainty. If you have pre-existing liver disease, this is a conversation worth having with your prescriber.

Side Effects in Children and Adolescents

LDN is increasingly being prescribed off-label for young people, particularly in the context of chronic conditions like Crohn’s disease and long COVID, and the pediatric safety picture is reassuring so far. A pilot study of children with moderate to severe Crohn’s disease found that LDN was well tolerated without any serious adverse events. Few side effects were reported, and there was no difference in complaints between children on naltrexone and those on placebo. Lab work showed no significant abnormalities in liver function, electrolytes, kidney markers, or blood sugar.⁶

A more recent study examining LDN prescribing for children and adolescents with long COVID found that about 71 percent experienced no adverse effects at all. Among those who did, the most common reports were vivid dreams or nightmares (about 10 percent), difficulty sleeping (also about 10 percent), fatigue (about 7 percent), and headaches (about 7 percent).⁷ The authors of that study raised a fair point: in a population already dealing with long COVID symptoms like fatigue, headaches, and sleep disturbance, it is hard to separate drug side effects from the illness itself. That ambiguity applies to adults with chronic conditions too. When you already feel lousy and start a new medication, distinguishing “the drug is doing this” from “my disease is doing this” is genuinely difficult.

How Dosing Strategy Affects What You Feel

LDN is most commonly prescribed at 4.5 mg taken once daily, but effective doses in the literature range from as low as 1 mg to as high as 6 mg. How quickly you get to your target dose might matter for both efficacy and side effects. A scoping review of LDN research noted that some studies used a gradual titration approach, starting at very low doses (as little as 0.1 mg) and slowly increasing, while others started patients directly at 4.5 mg.⁸

This is worth knowing if you experience noticeable side effects when you first start LDN, because starting lower and building up may make the adjustment smoother. The review noted that studies reporting ineffective treatment with LDN did not use titration, and that patients who had failed fixed-dose regimens sometimes responded successfully when switched to a gradual titration schedule. While the focus of that observation is on treatment efficacy rather than side effects, the principle of slower introduction applies to tolerability as well. If nausea, vivid dreams, or sleep disruption are bothering you in the first week at 4.5 mg, dropping to 1 mg or 1.5 mg and working up over a few weeks is a commonly used strategy among prescribers.

The timing of the dose also comes up frequently in patient communities. Many people take LDN at bedtime, partly because the vivid dream effect is less bothersome if it happens during sleep you are already getting. Others find that bedtime dosing worsens insomnia and switch to morning administration. There is no single correct timing, and individual response varies enough that trial and error is the norm.

Compounding and What Is Actually in Your Pill

Because LDN is almost always compounded rather than dispensed from a mass-manufactured tablet, what is in your capsule depends partly on the compounding pharmacy you use. Standard naltrexone tablets come in 50 mg, so producing a 1.5 or 4.5 mg dose means a compounding pharmacist is creating a custom preparation, usually by mixing a small amount of naltrexone with filler ingredients (excipients) to make a capsule of manageable size.

The excipient choice is not trivial. Some pharmacies use fillers like lactose, microcrystalline cellulose, or slow-release agents. People with lactose intolerance or celiac disease may react to certain fillers and mistakenly attribute the symptoms to naltrexone itself. If you develop gastrointestinal side effects that seem unusual, it is worth asking your pharmacy exactly what fillers they use and whether a reformulation is possible. Some patients who had GI trouble with one pharmacy’s formulation find it resolves completely when they switch to a different compounder using a different filler.

Compounded medications also lack the consistency guarantees of FDA-approved manufactured drugs. The actual dose in each capsule can vary slightly from pharmacy to pharmacy. For a drug used at such low doses, small variations in potency could plausibly affect both efficacy and side-effect intensity. This is not a reason to avoid LDN, but it is a reason to stick with a reputable compounding pharmacy and to think about the pharmacy as a variable if your experience changes unexpectedly.

Why LDN’s Side-Effect Profile Is Unusual

Most medications used for chronic pain and inflammatory conditions come with substantial side-effect baggage. Long-term NSAID use raises gastrointestinal and cardiovascular risks. Corticosteroids cause weight gain, bone loss, and metabolic disruption. Opioids carry dependence risks and cognitive effects. Immunosuppressants increase infection susceptibility. Compared to any of these, LDN’s profile of vivid dreams and occasional transient nausea is strikingly gentle.

Part of the reason may be the mechanism. Rather than continuously suppressing or activating a receptor system at high occupancy, LDN appears to work through a brief, intermittent nudge. The leading theory is that low-dose naltrexone temporarily and partially blocks opioid receptors and possibly Toll-like receptor 4, a component of the innate immune system that is widely expressed on immune cells in the brain and body.⁹ That brief blockade triggers a rebound effect: the body upregulates its own endorphin production and modulates inflammation. Because the drug’s actual receptor occupancy is so short-lived at these doses, the body is not being chronically pushed into an altered state the way it would be by, say, a daily steroid or a continuous opioid.

This rebound mechanism also explains why the vivid dream effect is so common. Endogenous opioid fluctuations during sleep can alter dream vividness and sleep architecture. For most people, the dreams are unusual but not distressing. A small percentage find them intense enough to be genuinely unpleasant, and that subset is the group most likely to benefit from dose timing changes or dose reduction.

When Side Effects Overlap with Symptoms

LDN is prescribed primarily for conditions that already produce fatigue, pain, brain fog, sleep disruption, and mood changes. Fibromyalgia, multiple sclerosis, Crohn’s disease, long COVID, and chronic pain syndromes all share many of the same symptoms that appear on LDN’s side-effect list. This creates a genuine attribution problem for patients and clinicians alike.

In the long COVID pediatric study, the researchers explicitly acknowledged that some reported side effects “may overlap with long COVID symptoms, suggesting reported effects could be attributed to long COVID rather than LDN.”⁷ The same logic applies to adults with fibromyalgia noticing more fatigue, or someone with Crohn’s disease having more GI upset. When your baseline already includes the very symptoms a drug might cause, it becomes genuinely hard to tell what is medication effect and what is disease fluctuation.

One practical approach is to pay close attention to timing. Side effects from LDN tend to appear within the first week or two and then fade, while disease symptoms follow the longer-term pattern of your condition. If a symptom shows up right after starting LDN, worsens for a week, and then resolves while you continue the medication, that pattern points toward a transient drug effect. If it persists or waxes and wanes in line with your usual flare pattern, the disease is the more likely culprit. Keeping a brief daily symptom diary for the first month of LDN can help you and your prescriber sort out what is actually happening.

LDN and Alcohol

Because standard-dose naltrexone is used to reduce alcohol cravings, people starting LDN sometimes wonder whether it will change their relationship with alcohol. At standard doses (50 mg), naltrexone blocks the pleasant opioid-mediated feelings that some people get from drinking, which can reduce the desire to drink. At low doses, that blockade is much briefer and less complete, so the anti-craving effect is not the primary purpose of the prescription.

That said, some LDN users anecdotally report that alcohol feels different or less appealing. A glass of wine might not produce the same warm glow it used to, or it might feel slightly more sedating. These reports are informal and have not been systematically studied in the LDN dose range. Since naltrexone is processed by the liver and alcohol adds its own hepatic burden, combining the two is something to discuss with your prescriber, particularly if you have any liver concerns. Most clinicians do not prohibit moderate alcohol use while on LDN, but they will want to know about your drinking habits when considering the prescription.

What the Evidence Still Lacks

The honest limitation of everything described above is that most LDN studies are small. The largest randomized controlled trial for fibromyalgia involved just under 100 participants. Many of the studies informing side-effect data are pilot trials, retrospective chart reviews, or case series. That is enough to conclude that LDN is not causing frequent or obvious harm, but it is not enough to detect rare side effects that might show up in one out of a thousand or ten thousand patients. Drugs that went through standard FDA approval pipelines are tested in thousands of people before reaching the market and then monitored in millions afterward. LDN has not had that level of scrutiny.

The compounding issue compounds the evidence gap (no pun intended). Because LDN is compounded, there is no single manufacturer running a pharmacovigilance program or collecting standardized adverse event reports the way there would be for a branded drug. Side-effect data accumulates piecemeal through academic studies, prescriber experience, and patient surveys rather than through a centralized reporting system. That means the absence of a particular rare side effect in the published literature carries less weight than it would for a drug with a robust post-market surveillance program. If you experience something unusual on LDN, reporting it to your prescriber and to the FDA’s MedWatch system adds to the collective knowledge base in a way that matters more than it would for a well-characterized mass-market drug.